Kota Itahashi

2.3k total citations · 1 hit paper
16 papers, 328 citations indexed

About

Kota Itahashi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Kota Itahashi has authored 16 papers receiving a total of 328 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Immunology. Recurrent topics in Kota Itahashi's work include Immune Cell Function and Interaction (5 papers), Lung Cancer Treatments and Mutations (5 papers) and Immunotherapy and Immune Responses (3 papers). Kota Itahashi is often cited by papers focused on Immune Cell Function and Interaction (5 papers), Lung Cancer Treatments and Mutations (5 papers) and Immunotherapy and Immune Responses (3 papers). Kota Itahashi collaborates with scholars based in Japan, United Kingdom and United States. Kota Itahashi's co-authors include Hiroyoshi Nishikawa, Shogo Kumagai, Takuma Irie, Noboru Yamamoto, Yasushi Goto, Yuichiro Ohe, Shohei Koyama, Yutaka Fujiwara, Sho Watanabe and Hidehito Horinouchi and has published in prestigious journals such as Nature Communications, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Kota Itahashi

16 papers receiving 327 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine

2024 74 citations Shogo Kumagai, Kota Itahashi et al. Nature Reviews Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kota Itahashi Japan	8	173	155	109	69	41	16	328
Nikolaus B. Wagner Germany	11	223 1.3×	139 0.9×	138 1.3×	48 0.7×	49 1.2×	22	340
Jenny Lazarus United States	7	254 1.5×	162 1.0×	121 1.1×	46 0.7×	44 1.1×	11	348
Zhuang Tong China	5	151 0.9×	96 0.6×	100 0.9×	66 1.0×	83 2.0×	5	272
Emily J. Lelliott Australia	9	195 1.1×	107 0.7×	181 1.7×	43 0.6×	25 0.6×	10	337
Won Seon Bang South Korea	9	256 1.5×	224 1.4×	124 1.1×	40 0.6×	61 1.5×	10	386
Xuejing Yang China	11	157 0.9×	137 0.9×	115 1.1×	47 0.7×	53 1.3×	22	294
Angela Sandru Romania	8	159 0.9×	53 0.3×	155 1.4×	38 0.6×	36 0.9×	11	299
Katriana Nugent United States	8	202 1.2×	109 0.7×	297 2.7×	61 0.9×	95 2.3×	14	460
Lei-Jie Dai China	5	182 1.1×	132 0.9×	149 1.4×	97 1.4×	93 2.3×	9	378

Countries citing papers authored by Kota Itahashi

Since Specialization

Citations

This map shows the geographic impact of Kota Itahashi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kota Itahashi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kota Itahashi more than expected).

Fields of papers citing papers by Kota Itahashi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kota Itahashi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kota Itahashi. The network helps show where Kota Itahashi may publish in the future.

Co-authorship network of co-authors of Kota Itahashi

This figure shows the co-authorship network connecting the top 25 collaborators of Kota Itahashi. A scholar is included among the top collaborators of Kota Itahashi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kota Itahashi. Kota Itahashi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Kumagai, Shogo, Kota Itahashi, & Hiroyoshi Nishikawa. (2024). Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine. Nature Reviews Clinical Oncology. 21(5). 337–353. 74 indexed citations breakdown →

Tsuge, Ayaka, Sho Watanabe, Akihito Kawazoe, et al.. (2024). The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment. Cancer Immunology Research. 13(2). 273–285. 6 indexed citations

Itahashi, Kota, Takuma Irie, Junichiro Yuda, et al.. (2022). BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors. Science Immunology. 7(76). eabk0957–eabk0957. 60 indexed citations

Itahashi, Kota, Takuma Irie, & Hiroyoshi Nishikawa. (2022). Regulatory T‐cell development in the tumor microenvironment. European Journal of Immunology. 52(8). 1216–1227. 52 indexed citations

Maeda, Yuka, Hisashi Wada, Daisuke Sugiyama, et al.. (2021). Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab. Nature Communications. 12(1). 7280–7280. 29 indexed citations

Toyozawa, Ryo, Kota Itahashi, Yutaka Fujiwara, et al.. (2021). 1292P Two single-arm, multicenter phase-II trials of PD-1 inhibitors in patients with pulmonary sarcomatoid carcinoma (NCCH1603/NCCH1703). Annals of Oncology. 32. S1002–S1003. 4 indexed citations

Kawazoe, Akihito, Kota Itahashi, Noboru Yamamoto, et al.. (2021). TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704). Clinical Cancer Research. 27(24). 6709–6715. 41 indexed citations

Kanda, Shintaro, Hideaki Shiraishi, Keiko Goto, et al.. (2019). Difference in central nerve system metastasis during gefitinib or erlotinib therapy in patients with EGFR-mutated non-small cell lung cancer: a retrospective study. Journal of Thoracic Disease. 11(4). 1347–1354. 4 indexed citations

Itahashi, Kota, Toshio Shimizu, Takafumi Koyama, et al.. (2018). Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991–2015. Investigational New Drugs. 37(1). 166–174. 4 indexed citations

10.

Itahashi, Kota, Shunsuke Kondo, Takashi Kubo, et al.. (2018). Evaluating Clinical Genome Sequence Analysis by Watson for Genomics. Frontiers in Medicine. 5. 305–305. 18 indexed citations

11.

Kondo, Shunsuke, et al.. (2017). Quality evaluation of investigator‐initiated trials using post‐approval cancer drugs in Japan. Cancer Science. 108(5). 995–999. 2 indexed citations

12.

Itahashi, Kota, Shintaro Kanda, Yuki Fujiwara, et al.. (2017). Dried plasma spot assay for sunitinib and its active metabolite by high performance liquid chromatography tandem mass spectrometry. Annals of Oncology. 28. x171–x171. 1 indexed citations

13.

Watanabe, Sho, Yasushi Goto, Noriko Motoi, et al.. (2017). P3.02c-097 Nivolumab in Elderly or Poor Performance Status Patients with Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(1). S1338–S1339. 2 indexed citations

14.

Asao, Tetsuhiko, Yutaka Fujiwara, Kota Itahashi, et al.. (2016). Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non–Small-Cell Lung Cancer: A Retrospective Analysis. Clinical Lung Cancer. 18(4). e251–e258. 11 indexed citations

15.

Fujiwara, Yutaka, Akinobu Hamada, Hidenori Mizugaki, et al.. (2016). Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism. Cancer Science. 107(8). 1117–1123. 17 indexed citations

16.

Aikawa, Hiroaki, Kota Itahashi, Shintaro Kanda, et al.. (2015). 449P Distribution of erlotinib to brain, tumor lesion and normal tissue analyzed by matrix assisted laser desorption/ionization mass spectrometry imaging and liquid chromatography-tandem mass spectrometry. Annals of Oncology. 26. ix125–ix125. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact